PREVIEW

New Bone-Strengthening Drug Abaloparatide Approved for Post-Menopausal Women by NHS. Tens of thousands of post-menopausal women could benefit from Abaloparatide, a new bone-strengthening drug approved by NICE for NHS use in England, BBC News reports. Abaloparatide can protect against osteoporosis, a bone-thinning condition that increases the risk of fractures in older women. The drug will be available on the NHS in England within the next three months, offering a new option for those who haven't responded to or can't tolerate existing treatments. The drug comes as a pre-filled pen for daily self-injection, encouraging cells to create new bone. Alison Smith, diagnosed with osteoporosis in 2011, said the new treatment would make a "big difference" for many patients reluctant to take current medications due to side effects. Dr. Nicky Peel from the Royal Osteoporosis Society confirmed that Abaloparatide is well-tolerated, despite some experiencing nausea, headaches, and palpitations early in the treatment. Dr. Peel emphasized the challenge of ensuring access to diagnostic services to identify patients who need the drug. The drug will be offered to those at high risk of fractures, with Theramex agreeing on a price with the NHS. Bone strength peaks in the mid-20s and declines naturally, making fractures more likely after minor falls in severe cases of bone loss. Women are more prone to osteoporosis due to menopause-related hormonal changes, with more than three million affected in the UK, and the prevalence increasing with age.
Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT